# Darapladib China PK

> **NCT02000804** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 24 (actual)

## Conditions studied

- Atherosclerosis

## Interventions

- **DRUG:** darapladib 160mg

## Key facts

- **NCT ID:** NCT02000804
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-23
- **Primary completion:** 2014-01-04
- **Final completion:** 2014-01-04
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02000804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02000804, "Darapladib China PK". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02000804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*